Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis

Kropholler, M. A.; Boellaard, Ronald; Elzinga, E. H.; Laken, Conny J. van der; Maruyama, K.; Kloet, Reina W.; Voskuyl, Alexandre E.; Dijkmans, Ben A. C.; Lammertsma, Adriaan A.

doi:10.1007/s00259-008-0987-7

Cited by 27 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The close similarity of the V T estimates indicates the negligible effect of labeled metabolites in these 2 small cohorts of patients. The same conclusion was reached by Kropholler et al in their study on the inflammation of knee joints in patients with rheumatoid arthritis using 11 C-(R)-PK11195 (22). The advantage of this approach is the simplification of the acquisition protocol, obviating the sampling and measurement of radiolabeled compounds in plasma.…”

Section: Discussionsupporting

confidence: 53%

“…The subsequent appearance of radiolabeled metabolites has only a small effect on the POB ratio, suggesting a similar partitioning of 11 C-(R)-PK11195 radioactivity and its radiolabeled metabolites between plasma and red blood cells. The POB ratio obtained in venous arterialized blood is approximately 10% smaller than the mean POB ratio of 1.55 reported by Kropholler et al for measurements obtained in arterial blood (22). In Figure 2, measurements of the parent fraction in plasma from previous studies with 11 C-(R)-PK11195 in humans (32)(33)(34)(35) are shown in comparison with our results.…”

Section: Discussionsupporting

confidence: 51%

“…Quantitative studies of inflammatory processes in the lungs (20,21) and joints (22,23) have been performed by means of kinetic modeling with plasma input functions (IFs) derived from direct blood sampling (20)(21)(22) or obtained from the blood pool in the image (24). The tissue uptake was expressed as tissue-over-plasma activity concentration ratio, and only the most recent of these studies used compartmental modeling to obtain total volume of distribution (V T ) estimates (22).…”

mentioning

confidence: 99%

“…The tissue uptake was expressed as tissue-over-plasma activity concentration ratio, and only the most recent of these studies used compartmental modeling to obtain total volume of distribution (V T ) estimates (22).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Detection and Quantification of Large-Vessel Inflammation with ¹¹C-(R)-PK11195 PET/CT

Hinz²,

et al. 2010

View full text Add to dashboard Cite

We investigated whether PET/CT angiography using 11 C-(R)-PK11195, a selective ligand for the translocator protein (18 kDa) expressed in activated macrophages, could allow imaging and quantification of arterial wall inflammation in patients with large-vessel vasculitis. Methods: Seven patients with systemic inflammatory disorders (3 symptomatic patients with clinical suspicion of active vasculitis and 4 asymptomatic patients) underwent PET with 11 C-(R)-PK11195 and CT angiography to colocalize arterial wall uptake of 11 C-(R)-PK11195. Tissue regions of interest were defined in bone marrow, lung parenchyma, wall of the ascending aorta, aortic arch, and descending aorta. Blood-derived and image-derived input functions (IFs) were generated. A reversible 1-tissue compartment with 2 kinetic rate constants and a fractional blood volume term were used to fit the time-activity curves to calculate total volume of distribution (V T ). The correlation between V T and standardized uptake values was assessed. Results: V T was significantly higher in symptomatic than in asymptomatic patients using both image-derived total plasma IF (0.55 6 0.15 vs. 0.27 6 0.12, P 5 0.009) and image-derived parent plasma IF (1.40 6 0.50 vs. 0.58 6 0.25, P 5 0.018). A good correlation was observed between V T and standardized uptake value (R 5 0.79; P 5 0.03). Conclusion: 11 C-(R)-PK11195 imaging allows visualization of macrophage infiltration in inflamed arterial walls. Tracer uptake can be quantified with image-derived IF without the need for metabolite corrections and evaluated semiquantitatively with standardized uptake values.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Discussionsupporting

confidence: 51%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Detection and Quantification of Large-Vessel Inflammation with ¹¹C-(R)-PK11195 PET/CT

Hinz²,

et al. 2010

View full text Add to dashboard Cite

show abstract

“…For example, Kropholler et al used PET to monitor macrophage migration into inflamed areas in rheumatoid arthritis using the ligand PK11195 coupled to a PET tracer, 11 C, which binds to benzodiazepine receptors on macrophages [125].…”

Section: Future Applications Of Hybrid Imaging With New Radiotracersmentioning

confidence: 99%

Prosthetic joint infections: radionuclide state-of-the-art imaging

Gemmel¹,

Wyngaert²,

Love

et al. 2012

Eur J Nucl Med Mol Imaging

170

151

View full text Add to dashboard Cite

Prosthetic joint replacement surgery is performed with increasing frequency. Overall the incidence of prosthetic joint infection (PJI) and subsequently prosthesis revision failure is estimated to be between 1 and 3%. Differentiating infection from aseptic mechanical loosening, which is the most common cause of prosthetic failure, is especially important because of different types of therapeutic management. Despite a thorough patient history, physical examination, multiple diagnostic tests and complex algorithms, differentiating PJI from aseptic loosening remains challenging. Among imaging modalities, radiographs are neither sensitive nor specific and cross-sectional imaging techniques, such as computed tomography and magnetic resonance imaging, are limited by hardware-induced artefacts. Radionuclide imaging reflects functional rather than anatomical changes and is not hampered by the presence of a metallic joint prosthesis. As a result scintigraphy is currently the modality of choice in the investigation of suspected PJI. Unfortunately, there is no true consensus about the gold standard technique since there are several drawbacks and limitations inherent to each modality. Bone scintigraphy (BS) is sensitive for identifying the failed joint replacement, but cannot differentiate between infection and aseptic loosening. Combined bone/gallium scintigraphy (BS/GS) offers modest improvement over BS alone for diagnosing PJI. However, due to a number of drawbacks, BS/GS has generally been superseded by other techniques but it still may have a role in neutropenic patients. Radiolabelled leucocyte scintigraphy remains the gold standard technique for diagnosing neutrophil-mediated processes. It seems to be that combined in vitro labelled leucocyte/bone marrow scintigraphy (LS/BMS), with an accuracy of about 90%, is currently the imaging modality of choice for diagnosing PJI. There are, however, significant limitations using in vitro labelled leucocytes and considerable effort has been devoted to developing alternative radiotracers, such as radiolabelled HIGs, liposomes, antigranulocyte antibodies and fragments, as well as more investigational tracers such as radiolabelled antibiotics, antimicrobial peptides, bacteriophages and thymidine kinase. On the other hand, positron emission tomography (PET) is still growing in the field of PJI imaging with radiotracers such as (18)F-fluorodeoxyglucose (FDG), (18)F-FDG white blood cells and (18)F-fluoride. But unfortunately this superb tomographic technique will only receive full acceptance when specific PET uptake patterns can be successfully developed. The emergence of hybrid modality imaging using integrated single photon emission computed tomography (SPECT) and PET with computed tomography (SPECT/CT and PET/CT) may also have a contributing role for more accurate assessment of joint replacement complications, especially combined with new radiotracers such as (68)Ga and (64)Cu. Finally, in searching for infection-specific tracers, currently there is no such diagnostic agent available.

show abstract

Evolving role of FDG PET imaging in assessing joint disorders: a systematic review

Carey

Saboury

Basu

et al. 2011

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Assessing joint disorders has been a relatively recent and evolving application of 18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging. FDG is taken up by inflammatory cells, particularly when they are active as part of an ongoing inflammatory process. Hence FDG PET has been employed to assess a wide array of arthritic disorders. FDG PET imaging has been investigated in various joint diseases for diagnostic purposes, treatment monitoring, and as a prognostic indicator as in other disorders. In some of the diseases the ancillary findings in FDG PET have provided important clues about the underlying pathophysiology and pathogenesis processes. While substantial promise has been demonstrated in a number of studies, it is clear that the potential utility of PET in this clinical realm far outweighs that which has been established to date.

show abstract

Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis

Cited by 27 publications

References 32 publications

Detection and Quantification of Large-Vessel Inflammation with ¹¹C-(R)-PK11195 PET/CT

Detection and Quantification of Large-Vessel Inflammation with ¹¹C-(R)-PK11195 PET/CT

Prosthetic joint infections: radionuclide state-of-the-art imaging

Evolving role of FDG PET imaging in assessing joint disorders: a systematic review

Contact Info

Product

Resources

About

Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis

Cited by 27 publications

References 32 publications

Detection and Quantification of Large-Vessel Inflammation with 11C-(R)-PK11195 PET/CT

Detection and Quantification of Large-Vessel Inflammation with 11C-(R)-PK11195 PET/CT

Prosthetic joint infections: radionuclide state-of-the-art imaging

Evolving role of FDG PET imaging in assessing joint disorders: a systematic review

Contact Info

Product

Resources

About

Detection and Quantification of Large-Vessel Inflammation with ¹¹C-(R)-PK11195 PET/CT

Detection and Quantification of Large-Vessel Inflammation with ¹¹C-(R)-PK11195 PET/CT